A single-cell analysis of roughly 12.4 million immune cells from more than 2,600 adults has produced a quantitative atlas of human immune aging — and identified a measurable ratio between two CD8 T cell subsets that tracks with a decade of downstream health outcomes in 50,000 UK Biobank participants.

The study, published in Immunity under the title "Single-cell analyses of global cohorts outline determinants of immune aging and link the ratio of GZMK+ to GZMB+ Tem cells to health trajectories," comes from scientists at Washington University School of Medicine in St. Louis, Nationwide Children's Hospital in Ohio, and King's College London. The cohort spanned ages 20 to over 90, drawn mainly from healthy adults across eight cohorts in North America, the UK, Asia, and Australia.

The core analytical finding is structural. Blood from younger participants was uniformly enriched with naive immune cells — cells not yet exposed to specific pathogens and still adaptable to new infections or vaccines. Older immune systems showed no such uniformity. Some older participants carried a greater abundance of immune cells reflecting inflammation; others did not.

What ratio did the researchers measure?

The team placed each participant on a spectrum defined by the ratio between two white blood cell populations: granzyme B-producing cells and granzyme K-producing cells. Both fall within effector memory CD8 T cells, which use granzymes to destroy target cells or coordinate immune responses.

The two subsets play different roles. Granzyme B-producing cells act as direct destroyers of diseased cells. Granzyme K-producing cells have drawn less study and may work to boost immune responses.

A healthy immune system gradually shifts toward granzyme K cells over time. An immune system that leans toward granzyme B cells signals unhealthy aging — and individuals can reach that granzyme B-dominant state much earlier in life.

How did they validate it against real outcomes?

Cell-level data alone cannot answer whether the ratio predicts disease. So the researchers turned to the UK Biobank, which holds protein information but lacks CD8 T cell counts.

To bridge that gap, they built a computational model trained on a smaller dataset of apparently healthy adults that contained both CD8 T cell counts and blood protein measurements. The model mapped the protein signatures left behind when either granzyme B-producing or granzyme K-producing cells dominated.

The team then applied the model to baseline blood protein samples from 50,000 UK Biobank participants, calculating each person's position on the immune cell spectrum.

The results separated cleanly into measured outcomes rather than projections:

• Healthy adults whose baseline immune profile leaned heavily toward granzyme B cells showed a higher risk of death a decade later than those with more granzyme K cells.
• The granzyme B-dominant group was also more likely to develop chronic conditions over the following decade, including Type 2 diabetes, hypertension, liver disease, and renal failure, among others.

"A higher level of granzyme B cells in a healthy state means the immune system might be already reacting to something," said Marina Terekhova, MD, a professor in pathology and immunology at WashU Medicine and a co-author on the paper. "It isn't a formal disease diagnosis, but it may indicate the body is off track."

Why do two people born the same year age differently?

The findings offer a mechanistic answer to that question. Because individuals can arrive at the granzyme B-dominant state at very different points in life, their immune systems age on divergent trajectories. Two people born in the exact same year can therefore carry different risks for chronic disease and death decades later.

The findings point to "clues in the blood that can tell us whether someone is on a healthy or unhealthy aging trajectory," said Maxim Artyomov, PhD, the alumni endowed professor of pathology and immunology at WashU Medicine and one of the paper's corresponding authors.

What is the translational path?

Artyomov and his lab are now adapting the research into a simple blood test processable with standard equipment — a key constraint for any eventual clinical deployment, since it removes the need for specialized single-cell instrumentation.

"Identifying specific biological red flags in the immune system could pave the way for early-warning tests that spot disease risks years before a clinical diagnosis," Artyomov said.

For R&D managers in diagnostics and immunology, the study's methodological template — single-cell discovery in a multi-cohort discovery set, followed by proteomic proxy modeling scaled to a 50,000-participant biobank — may prove as reusable as the granzyme ratio itself.